Amanda Keys
Family · Lafayette, LANPI 1215145164
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,750 of the $27,023 with a category attached, or 69.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 72.8% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $7,217 and has fallen 85.6% since, to $1,041 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $78.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
- Abbott$2K
- Pfizer$912
- Novartis$590
- E.r. Squibb & Sons, L.L.C.$520
- AstraZeneca$438
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$18,75069%
- Travel & lodging$1,0504%
- Food & beverage$7,22327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 51 | $19,667 |
| Abbott | 31 | $1,876 |
| Pfizer | 61 | $912 |
| Novartis | 37 | $590 |
| E.r. Squibb & Sons, L.L.C. | 38 | $520 |
| AstraZeneca | 12 | $438 |
| Amgen | 13 | $402 |
| Abiomed | 6 | $351 |
| Boston Scientific | 7 | $254 |
| Merck | 14 | $251 |
| Johnson & Johnson | 17 | $240 |
| Esperion Therapeutics, Inc. | 12 | $224 |
| Boehringer Ingelheim | 11 | $211 |
| Impulse Dynamics (USA) Inc. | 2 | $160 |
| Novo Nordisk | 7 | $128 |
| Cardiovascular Systems Inc. | 1 | $121 |
| Amarin Pharma, Inc. | 6 | $109 |
| Heartflow, Inc. | 1 | $98 |
| Philips North America LLC | 1 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Recor Medical Inc | 2 | $52 |
| Silk Road Medical, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Itamar Medical Inc | 1 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $35 |
| Cvrx, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$18,750
- CARDIOMEMS$1,205
- OPTIMIZER$260
- FARXIGA$254
- Impella$243
- Repatha$236
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$135
- Diamondback Peripheral$121
- JARDIANCE$111
How this compares
$27,023 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $135,249 |
| EntrestoSacubitril/Valsartan | 49 | $43,276 |
| XareltoRivaroxaban | 40 | $34,551 |
| JardianceEmpagliflozin | 33 | $22,669 |
| Repatha SureclickEvolocumab | 22 | $16,265 |
| Ranolazine ErRanolazine | 79 | $4,217 |
| Atorvastatin Calcium | 300 | $2,968 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 156 | $2,879 |
| ClopidogrelClopidogrel Bisulfate | 210 | $2,088 |
| Metoprolol Succinate | 198 | $1,990 |
| Amiodarone Hcl | 52 | $1,256 |
| Midodrine Hcl | 23 | $1,024 |
| Potassium Chloride | 78 | $1,023 |
| Furosemide | 192 | $888 |
| Losartan Potassium | 80 | $826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $912 | $135,249129 claims |
| NovartisEntresto | $590 | $43,27649 claims |
| Johnson & JohnsonXarelto | $240 | $34,55140 claims |
| Boehringer IngelheimJardiance | $211 | $22,66933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Lafayette
- Rebekah GarrardLafayette$105K
- Jorge MenaLafayette$27K
- Shanna JohnsonLafayette$22K
- Layne LemaireLafayette$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.